Bidil and Hyperkalemia - a phase IV clinical study of FDA data

Summary:

Hyperkalemia is reported as a side effect among people who take Bidil (hydralazine hydrochloride; isosorbide dinitrate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Lasix, and have High blood pressure.

The phase IV clinical study analyzes which people have Hyperkalemia when taking Bidil. It is created by eHealthMe based on reports of 511 people who have side effects when taking Bidil from the FDA, and is updated regularly.

What is Bidil?

Bidil has active ingredients of hydralazine hydrochloride; isosorbide dinitrate. eHealthMe is studying from 520 Bidil users. Check the latest studies of Bidil.

What is Hyperkalemia?

Hyperkalemia (damage to or disease of the kidney) is found to be associated with 1,954 drugs and 2,940 conditions by eHealthMe. Check the latest studies of Hyperkalemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 17, 2026

511 people reported to have side effects when taking Bidil.
Among them, 15 people (2.94%) have Hyperkalemia.

Among these 15 people:

How long have people been on Bidil when they have Hyperkalemia? *

What is the gender of people who have Hyperkalemia when taking Bidil? *

female: 60 %
male: 40 %

What is the age of people who have Hyperkalemia when taking Bidil? *

What are other drugs people take besides Bidil? *

What are other side effects people have besides Hyperkalemia? *

Dyspnea (difficult or laboured breathing): 3 people, 20.00%
High Blood Pressure: 3 people, 20.00%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 3 people, 20.00%
Cardiac Failure Congestive: 3 people, 20.00%
Weakness: 3 people, 20.00%
Eating Disorder: 2 people, 13.33%
Hypotension (abnormally low blood pressure): 2 people, 13.33%
Headache (pain in head): 2 people, 13.33%
Enlarged Heart: 2 people, 13.33%
Ejection Fraction Decreased (systolic heart failure): 2 people, 13.33%

What are the existing conditions these people have? *

High Blood Pressure: 3 people, 20.00%
Cardiac Failure Congestive: 2 people, 13.33%
Type 2 Diabetes: 1 person, 6.67%
Fluid Overload (too much fluid in the blood): 1 person, 6.67%
Asthma: 1 person, 6.67%
Bacterial Infection: 1 person, 6.67%
Cardiac Failure: 1 person, 6.67%
Cardiomyopathy (weakening of the heart muscle): 1 person, 6.67%
Chronic Kidney Disease: 1 person, 6.67%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Bidil and have Hyperkalemia?

- Check whether Hyperkalemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Bidil:

Bidil (520 reports)

Hyperkalemia treatments and more:

Hyperkalemia (78,084 reports)

How severe was Hyperkalemia and when was it recovered:

Hyperkalemia in Bidil

Expand to all the drugs that have ingredients of hydralazine hydrochloride; isosorbide dinitrate:

Hyperkalemia and drugs with ingredients of hydralazine hydrochloride; isosorbide dinitrate (14 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Bidil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperkalemia:

Hyperkalemia (1,954 drugs)

Browse all the conditions that are associated with Hyperkalemia:

Hyperkalemia (2,940 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydralazine hydrochloride; isosorbide dinitrate (the active ingredients of Bidil) and Bidil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.